Arrow International hemodialysis and AHDC kits recalled for contaminated injectable anesthetics and saline
Arrow International hemodialysis kits recalled for contaminated anesthetics
Arrow International included lidocaine, bupivacaine, and saline solution from a supplier with quality issues in multiple hemodialysis and AHDC kits. The supplier's products have been linked to drug ineffectiveness and potential sterility failures. Compromised sterility in injectable products can cause serious or life-threatening infections.
- Check if your hemodialysis or AHDC kit matches one of the recalled models and lot numbers listed by the FDA.
- Do not use recalled kits. Contact your healthcare provider or dialysis center immediately.
- Return unused kits to your supplier or manufacturer for replacement.
Lidocaine, Bupivacaine, and 0.9% sodium chloride, the subject of a supplier recall, were included into kits and sets. The supplier was found to have quality issues and limited reports of drug ineffectiveness, and if sterility of a water-based injectable product is compromised this could lead to serious or life-threatening injuries.
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=Z-2388-2026More Arrow recalls
- FDA-Device2026-06-24Arrow International hemodialysis kits recalled for contaminated anesthetic and saline solutions
- FDA-Device2026-06-24Arrow International PI CVC kits recalled for compromised sterility and drug ineffectiveness
- FDA-Device2026-06-24Arrow International PICC kits and stylets recalled for compromised sterility and drug ineffectiveness
- FDA-Device2026-06-24Arrow International PICC and JACC catheter kits recalled for contaminated anesthetic and saline components
- FDA-Device2026-06-24Arrow International Pacing PSI Kits recalled for potential drug ineffectiveness and sterility compromise
Don't want to check this manually?
We email you a Sunday digest of new federal recalls relevant to your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.
Get the Sunday Brief